Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 65 years old
- People who have been diagnosed with a condition called metabolic-associated fatty liver disease (MAFLD), which is a type of liver disease linked to metabolism problems
- People whose liver is enlarged by a certain amount, confirmed by an ultrasound scan
- People whose liver enzyme levels (a marker called ALT) fall within a specific range shown on a blood test
- People who have a significant amount of fat in their liver, measured using a specialist scan called a FibroScan
- People who have a certain level of liver stiffness (which can indicate scarring), also measured by FibroScan
- People who are able to follow the study procedures throughout the trial
- People who have read and signed a consent form agreeing to take part
Who may not be able to join:
- People who have advanced liver scarring (cirrhosis) or liver cancer
- People who are pregnant or currently breastfeeding
- People who have a known allergy to any of the medications or supplements used in the study
- People who have gallstones or a blockage in the bile ducts
- People whose liver appears shrunken on a scan
- People who have cysts on their liver
- People who have any abnormal growths or nodules found on their liver
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +79091846111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Reduction in ALT levels by ≥30% from baseline; Change in liver size (ultrasound); Improvement in steatosis/fibrosis (FibroScan)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.